On page 27-28 of the English translation of the specification, please amend claim 1 to read as follows:

1. A compound of having the chemical structure of formula (A):

X
$$R_1 R_2 R_3 Q R_4 N \langle \frac{y}{z} \rangle$$

(A)

with peripheral analgesic effect, wherein:

- a) X is selected from the group consisting of H and C_{1-6} alkyl;
- b) Y and Z are independently selected from the group consisting of H, cyclic aralkyl, and C₁₋₆ alkyl;
- c) R_1 is a tyrosyl residue or a 2'.6'-dimethyltyrosyl residue:
- d) R₂ is an amino acid having the R-configuration,
 aminoisobutyric acid, cyclopropylalanine, cyclohomoleucine or
 cycloleucine;
- e) R_3 is an aromatic amino acid;
- f) R_4 is an aromatic amino acid residue;
- g) Q is an amide bond or an interposed amide bond mimetic;
- h) with the proviso that when:
 - i) R_1 is a tyrosyl residue;
 - ii) R_2 is D-alanine;
 - iii) X, Y, and Z are 11; and
 - iv) R_3 is phenylalanine;

then R₄ is not unsubstituted phenylalanine or phenylalanine substituted with 4NO₂ or 4N₃:

- i) with the further proviso that when:
 - i) R_1 is a tyrosyl residue:
 - ii) R_2 is D-alanine:
 - iii) X, Y, and Z are H; and
 - ity Pois phony lalanine.

j) with the further proviso that when:

- i) R_1 is a tyrosyl residue:
- ii) R_2 is D-alanine:
- iii) X, Y, and Z are II; and
- iv) R_4 is 1'-naphthylalanine;

then R₃ is not 1'-naphthylalanine or 2'-naphthylalanine:

k) with the further proviso that when:

- i) R_1 is a tyrosyl residue:
- ii) R₂ is D-alanine; and
- iii) X. Y and Z are H.

then both R₃ and R₄ are not tryptophan;

- 1) with the further proviso that when:
 - i) R_1 is a tyrosyl residue:
 - ii) R₂ is a D-amino acid with a lower alkyl or lower thioalkyl group as a side chain; and
 - iii) R_4 is a neutral amino acid,

then R₃ is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting

of:

H-Tyr-D-Phe-Phe-NH₂;

H-Tyr-D-NMePhe-Phe-Phe-NH₂;

11-Tyr-D-Tic-Phe-Phe-NH₂:

H-Tyr-Pro-Phe-Thr(Bz1)-NH₂: (SEQ ID NO:2)

H-Tvr-Pro-Phe-Phe-NH₂: (SEQ ID NO:1)

H-Tvr-Pro-Phe-Apb-NH₂;

H-Tvr-Pro-Phe-App-NH2:

H-Tvr-Pro-Phe-Aph-NH2; and

H-Tyr-Pro-Apb-Phe-NII₂;

wherein Apb is 2-amino-4-phenylbutanoic acid. App is

2-amino-5-phenylpentanoic acid and Aph is 2-amino-6-phenylhexanoic acid.

to read as follows:

15. A compound selected from the group consisting of:

H-Tyr-Aib-Phe-Phe-NH₂:

H-Tyr-D-Nle-Phe-Phe-NII₂;

H-Tyr-D-Ala-Phe-2'-Nal-NH₂;

H-Tyr-D-Ala-D-Phe-Phe-NH₂;

H-Tyr-D-Ala-Phe(4NO₂)-Phe(4NO₂)-NH₂;

H-Tyr-D-Ala-Phe-Tic-NH₂;

H-Tyr-D-Ala-Phe-Phe(NMe)-NH₂;

H-Tyr-D-Ala-Phe-I'-Nal-NH₂;

11-Tyr-D-Ala-Trp-Phe-NH₂;

H-Tyr-D-Ala-Phe-Trp-NH₂;

II-Tyr-∇Ala-Phe-Phe-NH₂; (SEQ ID NO:3)

 ∇ CII₂-Tyr-D-Ala-Phe-Phe-NH₂;

H-Tyr-D-Nle-Phe-Trp-NH₂;

H-Tyr-D-Nle-Phe-2'-Nal-NH₂;

H-Tyr-D-Nle-Trp-Phe-NH₂;

H-Tyr-D-Ala-Trp-2'-Nal-NH₂;

H-Tyr-D-Nle-Trp-2'-Nal-NH₂;

H-Tyr-D-NIe-Trp-Trp-NH₂;

H-Tyr-D-Nva-Phe-Phe-NH₂:

H-Tyr-D-Ser-Phe-Phe-NH₂;

H-Tyr-D-Val-Phe-Phe-NH₂;

II-Tyr-D-Leu-Phe-Phe-NII₂:

H-Tyr-D-He-Phe-Phe-NH₂:

H-Tvr-D-Abu-Phe-Phe-NH₂;

H-Tyr-Chl-Phe-Phe-NH₂:

H-Tyr-Cle-Phe-Phe-NII₂;

H-Tvr-D-Arg-Phe-Phe-NH₂:

H-Tvr-D-Cys-Phe-Phe-NII₂:

H-Evr-D- Ma-Phe-Phe-OH trifluoroacetate.

11-Tyr-D-Ala-Phe-Phg-NH2 trifluoroacetic acid salt; H-Tyr-D-Arg-Phe-Hph-NH2 bis-trifluoroacetic acid: 11-DMT-D-Ala-Phe-Phe-NH2 trifluoroacetic acid; H-D-DMT-D-Ala-Phe-Phe-NH2 trifluoroacetic acid salt: H-Tyr-D-Ala-Phe-Hph-NH2 trifluoroacetic acid salt: H-Tyr-D-Ala-Phe-Cys(Bzl)-NH2 trifluoroacetic acid salt: H-Tyr-D-Arg-Hph-Phe-NH2 bis-trifluoroacetic acid salt; H-Tyr-D-Arg-Phg-Phe-NH₂ bis-trifluoro acetic acid salt; H-Tvr-D-Ala-Phe-Phe-CH₂OH hydrochloride salt; H-Tyr-D-Ala-Hph-Phe-NH2 trifluoroacctic acid salt: H-Tyr-D-Met-Phe-Phe-NH₂ trifluoroacetic acid salt: H-Tyr-D-Arg-Phe-D-Phe-NH₂ bis-trifluoroacetic acid salt:. H-Tyr-D-Ala-Phg-Phe-NH2 trifluoroacetic acid salt; H-Tyr-(D)-Ala-(D)-Phg-Phe-NH2 trifluoroacetic acid salt: H-Tyr-D-Arg-Phe-Phe(pF)-NH2 bis-trifluoroacctic acid salt; H-Tyr-D-Arg-Phe-D-Phe(pF)-NH2 ditrifluoroacetic acid salt: H-Tyr-D-Ala-Phe-Phe(pF)-NH2 trifluoroacetic acid salt: and H-Tyr-D-Ala-Phe-D-Phe(pF)-NH2 trifluoroacetic acid salt.

On page 33-35 of the English translation of the specification, please amend claim 18 to read as follows:

 A pharmaccutical composition possessing analgesic activity, comprising, in admixture with a pharmaccutically acceptable carrier, an effective amount of a least one compound having the chemical structure of formula (A):

$$X - R_1 - R_2 - R_3 - Q - R_4 - N \langle Z \rangle^{F}$$

(A)

with peripheral analgesic effect, wherein:

evene aralky), and C. Caiky).

c) R_1 is a tyrosyl residue or a 2'.6'-dimethyltyrosyl residue:

- R₂ is an amino acid having the R-configuration, aminoisobutyric acid,
 eyclopropylalanine, cyclohomoleucine or cycloleucine;
- e) R_3 is an aromatic amino acid:
- f) R_4 is an aromatic amino acid residue:
- g) Q is an amide bond or an interposed amide bond mimetic:
- h) with the proviso that when:
 - i) R_1 is a tyrosyl residue;
 - ii) R_2 is D-alanine;
 - iii) X, Y, and Z are H; and
 - iv) R₃ is phenylalanine;

then R_4 is not unsubstituted phenylalanine or phenylalanine substituted with $4NO_2$ or $4N_3$;

- i) with the further proviso that when:
 - i) R_1 is a tyrosyl residue;
 - ii) R_2 is D-alanine;
 - iii) X, Y, and Z are H; and
 - iv) R_4 is phenylalanine;

then R₃ is not unsubstituted phenylalanine or phenylalanine substituted with 4NO₂;

- j) with the further proviso that when:
 - i) R_1 is a tyrosyl residue:
 - ii) R_2 is D-alanine:
 - iii) X, Y, and Z are H; and
 - iv) R₄ is 1'-naphthylalanine:

then R₃ is not 1'-naphthylalanine or 2'-naphthylalanine:

- k) with the further proviso that when:
 - i) R_1 is a tyrosyl residue:
 - ii) R_2 is D-alanine: and
 - iii) X, Y and Z are II.
 - R is a tyrosyl residue;

ii) R₂ is a D-amino acid with a lower alkyl or lower thioalkyl group as a side chain; and

iii) R_4 is a neutral amino acid.

then R₃ is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting of:

H-Tyr-D-Phe-Phe-Phe-NH₂;

H-Tyr-D-NMePhe-Phe-NH₂;

H-Tyr-D-Tic-Phe-Phe-NH₂;

H-Tyr-Pro-Phe-Thr(Bzl)-NH₂; (SEQ ID NO:2)

H-Tyr-Pro-Phe-Phe-NH₂; (SEQ ID NO:1)

H-Tyr-Pro-Phe-Apb-NH₂;

H-Tyr-Pro-Phe-App-NH₂;

H-Tyr-Pro-Phe-Aph-NH₂; and

H-Tyr-Pro-Apb-Phe-NH₂;

wherein Apb is 2-amino-4-phenylbutanoic acid. App is

2-amino-5-phenylpentanoic

acid and Aph is 2-amino-6-phenylhexanoic acid.

On page 38-40 of the English translation of the specification, please amend claim 30 to read as follows:

30. A method for the treatment of pain comprising the step of administering to a mammal in need of such treatment a pharmaceutically effective amount of at least one compound having the chemical structure of formula (A):

$$X - R_1 - R_2 - R_3 - Q - R_4 - N \langle \rangle$$

(A)

wherein:

a) X is selected from the group consisting of H and C_{1-6} alkyl:

 $C_1 = -R_1$ is a tyrosyl residue of a $\pm .0$ -dimethyllylosyl (esidde.)

d) R_2 is an amino acid having the R-configuration, aminoisobutyric acid.

evelopropylalanine, cyclohomoleucine or cycloleucine:

- R₃ is an aromatic amino acid: e)
- R₄ is an aromatic amino acid residue: Ð
- Q is an amide bond or an interposed amide bond mimetie: g)
- with the proviso that when: h)
 - i) R_1 is a tyrosyl residue;
 - ii) R₂ is D-alanine:
 - iii) X, Y, and Z are H; and
 - R₃ is phenylalanine; iv)

then R4 is not unsubstituted phenylalanine or phenylalanine substituted with 4NO₂ or 4N₃;

- i) with the further proviso that when:
 - R₁ is a tyrosyl residue; i)
 - ii) R₂ is D-alanine;
 - X, Y, and Z are H; and iii)
 - R₄ is phenylalanine; iv)

then R₃ is not unsubstituted phenylalanine or phenylalanine substituted with 4NO₂;

with the further proviso that when: **j**)

- R₁ is a tyrosyl residue: i)
- R₂ is D-alanine: ii)
- X, Y, and Z are H: and iii)
- R₄ is 1'-naphthylalanine: iv)

then R₃ is not 1'-naphthylalanine or 2'-naphthylalanine:

with the further proviso that when: k)

- R₁ is a tyrosyl residue: i)
- R2 is D-alanine: and ii)
- iii) X. Y and Z are H.

then both R3 and R4 are not tryptophan:

Ry is a D-amino acid with a lower alkyr or lower thioalkyr

11)

group as a side chain; and

iii) R_4 is a neutral amino acid,

then R₃ is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting of:

H-Tyr-D-Phe-Phe-NH₂;

H-Tyr-D-NMePhe-Phe-Phe-NH₂;

H-Tyr-D-Tic-Phe-Phe-NH₂;

H-Tyr-Pro-Phe-Thr(Bzl)-NH₂; (SEQ 1D NO:2)

11-Tyr-Pro-Phe-Phe-NH₂; (SEQ ID NO:1)

H-Tyr-Pro-Phe-Apb-NH₂;

H-Tyr-Pro-Phe-App-NH₂;

H-Tyr-Pro-Phe-Aph-NH₂; and

H-Tyr-Pro-Apb-Phe-NH₂;

wherein Apb is 2-amino-4-phenylbutanoic acid. App is

2-amino-5-phenylpentanoic acid and Aph is 2-amino-6-phenylhexanoic acid.

On page 41-43 of the English translation of the specification, please amend Claim 37 to read as follows:

37. A method for the treatment of pain comprising the step of administering to a mammal in need of such treatment a pharmaceutically effective amount of a pharmaceutical composition possessing analgesic activity, wherein said pharmaceutical composition comprises, in admixture with a pharmaceutically acceptable carrier, an effective amount of at least one compound having the chemical structure of formula (Λ):

X R₁ R₂ R₃ Q R₄ N
$$\langle \frac{1}{Z} \rangle$$

a barrier

cyclic aralkyl, and C₁₋₆ alkyl:

Brown, *et al.* 09/994,078

- e) R_1 is a tyrosyl residue or a 2',6'-dimethyltyrosyl residue:
- d) R₂ is an amino acid having the R-configuration, aminoisobutyric acid,
 cyclopropylalanine, cyclohomoleucine or cycloleucine;
- e) R_3 is an aromatic amino acid;
- f) R_4 is an aromatic amino acid residue:
- g) Q is an amide bond or an interposed amide bond mimetic;
- h) with the proviso that when:
 - i) R_1 is a tyrosyl residue;
 - ii) R_2 is D-alanine:
 - iii) X, Y, and Z are H; and
 - iv) R_3 is phenylalanine;

then R₄ is not unsubstituted phenylalanine or phenylalanine substituted with

4NO₂ or 4N₃;

- i) with the further proviso that when:
 - i) R_1 is a tyrosyl residue;
 - ii) R_2 is D-alanine;
 - iii) X, Y, and Z are H; and
 - iv) R_4 is phenylalanine;
 - then R₃ is not unsubstituted phenylalanine or phenylalanine substituted with 4NO₂;
- j) with the further proviso that when:
 - i) R_1 is a tyrosyl residue:
 - ii) R_2 is D-alanine;
 - iii) X, Y, and Z are 11; and
 - iv) R_4 is 1'-naphthylalanine:
 - then R₃ is not 1'-naphthylalanine or 2'-naphthylalanine:
- k) with the further proviso that when:
 - i) R_1 is a tyrosyl residue:

then both R , and R ; are not tryptophan.

- 1) with the further proviso that when:
 - i) R_1 is a tyrosyl residue:
 - R₂ is a D-amino acid with a lower alkyl or lower thioalkyl group as a side chain; and
 - iii) R_4 is a neutral amino acid,

then R₃ is not unsubstituted phenylalanine;

m) and wherein said compound is not selected from the group consisting

of:

H-Tyr-D-Phe-Phe-Phe-NH₂;

H-Tyr-D-NMePhe-Phe-Phe-NH₂;

H-Tyr-D-Tic-Phe-Phe-NH₂;

H-Tyr-Pro-Phe-Thr(Bz1)-NH₂; (SEQ ID NO:2)

H-Tyr-Pro-Phe-Phe-NH₂; (SEQ ID NO:1)

H-Tyr-Pro-Phe-Apb-NH₂;

H-Tyr-Pro-Phe-App-NH₂;

H-Tyr-Pro-Phe-Aph-NH₂; and

H-Tyr-Pro-Apb-Phe-NH₂;

wherein Apb is 2-amino-4-phenylbutanoic acid. App is

2-amino-5-phenylpentanoic acid and Aph is 2-amino-6-phenylhexanoic acid.

On page 46-47 of the English translation of the specification, please amend claim 51 to read as follows:

51. A pharmaceutical composition having analgesic activity, comprising in admixture with a pharmaceutically acceptable carrier, an effective amount of at least one peptide selected from the group consisting of: H-Tyr-Aib-Phe-Phe-NH₂: H-Tyr-D-Nle-Phe-NH₂: H-Tyr-D-Ala-Phe-2'-Nal-NH₂: H-Tyr-D-Ala-D-Phe-Phe-NH₂:

H-Ivr-D-Ala-Phe-Phe(NMe)-NH).

H-Tyr-D-Ala-Phe-1'Nal-NH₂; H-Tvr-D-Ala-Trp-Phe-NH₂; H-Tyr-D-Ala-Phe-Trp-NH₂: H-Tyr-∇Ala-Phe-Phe-NH₂; (SEQ ID NO:3) ∇ CH₂-Tyr-D-Ala-Phe-Phe-NH₂: H-Tyr-D-Nle-Phe-Trp-NH₂; H-Tyr-D-Nle-Phe-2'-Nal-NH₂; H-Tyr-D-Nle-Trp-Phe-NH₂; H-Tyr-D-Ala-Trp-2'-Nal-NH₂; H-Tyr-D-Nle-Trp-2'-Nal-NH₂; H-Tyr-D-Nle-Trp-Trp-NH₂; H-Tyr-D-Nva-Phe-Phe-NH₂; H-Tyr-D-Ser-Phe-Phe-NH₂; H-Tyr-D-Val-Phe-Phe-NH₂; H-Tyr-D-Leu-Phe-Phe-NH₂; H-Tyr-D-Ile-Phe-Phe-NH₂; H-Tyr-D-Abu-Phe-Phe-NH₂: H-Tyr-Chl-Phe-Phe-NH₂; H-Tyr-Cle-Phe-Phe-NH₂; 11-Tyr-D-Arg-Phe-Phe-NH₂: H-Tvr-D-Cys-Phe-Phe-NH₂; H-Tyr-D-Thr-Phe-Phe-NH₂; H-DMT-D-Ser-Phe-Phe-NH₂: H-Tyr-D-Ala-Phe-Phe-OII trifluoroacetate: H-Tyr-D-Ala-Phe-Phg-NH₂ trifluoroacetic acid salt: H-Tyr-D-Arg-Phe-Hph-NH₂ bis-trifluoroacetic acid: H-DMT-D-Ala-Phe-Phe-NH₂ trifluoroacetic acid: H-D-DMT-D-Ala-Phe-Phe-NH₂ trifluoroacetic acid salt:

H-Tyr-D-Ala-Phe-Hph-NH₂ trifluoroacetic acid salt:

H-1vr-D-Arg-Phg-Phe-NH: bis-trifluoro acetic acid salt.

H-Tyr-D-Ala-Phe-Phe-CH₂OH hydrochloride salt: II-Tyr-D-Ala-Hph-Phe-NH₂ trifluoroacetic acid salt: II-Tyr-D-Met-Phe-Phe-NH₂ trifluoroacetic acid salt: II-Tyr-D-Arg-Phe-D-Phe-NH₂ bis-trifluoroacetic acid salt: II-Tyr-D-Ala-Phg-Phe-NH₂ trifluoroacetic acid salt: II-Tyr-(D)-Ala-(D)-Phg-Phe-NH₂ trifluoroacetic acid salt: H-Tyr-D-Arg-Phe-Phe(pF)-NH₂ trifluoroacetic acid salt: H-Tyr-D-Arg-Phe-D-Phe(pF)-NH₂ ditrifluoroacetic acid salt: H-Tyr-D-Ala-Phe-Phe(pF)-NH₂ trifluoroacetic acid salt: H-Tyr-D-Ala-Phe-Phe(pF)-NH₂ trifluoroacetic acid salt:

On page 48-49 of the English translation of the specification, please amend claim 55 to read as follows:

A method for the treatment of pain, comprising the step administering to a 55. mammal in need of such treatment a pharmaceutically effective amount of a peptide sclected from the group consisting of: H-Tyr-Aib-Phe-Phe-NH₂; H-Tyr-D-NIe-Phe-Phe-NH₂; H-Tyr-D-Ala-Phe-2'-Nal-NH₂; H-Tyr-D-Ala-D-Phe-Phe-NH₂; H-Tyr-D-Ala-Phe(4NO₂)-Phe(4NO₂)-NH₂; H-Tyr-D-Ala-Phc-Tic-NH₂; H-Tvr-D-Ala-Phc-Phc(NMe)-NH₂: H-Tyr-D-Ala-Phe-FNal-NH₂: H-Tyr-D-Ala-Trp-Phe-NH₂: H-Tyr-D-Ala-Phe-Trp-NH₂: H-Tyr-∀Ala-Phe-Phe-NH₂; (SEQ ID NO:3) ∇ CH₂-Tvr-D-Ala-Phe-Phe-NH₂: H-Tvr-D-Nle-Phe-Trp-NH₂:

H-1yr-D-Ma-1rp-2'-Nal-NH2.

Brown, et al. 09 994,078

II-Tvr-D-Nle-Trp-2'-Nal-NH₂: II-Tvr-D-Nle-Trp-Trp-Nll₂; H-Tvr-D-Nva-Phe-Phe-NH₂: II-Tvr-D-Ser-Phe-Phe-NH₂: H-Tvr-D-Val-Phe-Phe-NH₂; H-Tyr-D-Leu-Phe-Phe-NH₂; H-Tyr-D-lle-Phe-NH₂; H-Tyr-D-Abu-Phe-Phe-NH₂; H-Tyr-Chl-Phe-Phe-NH₂: H-Tyr-Cle-Phe-Phc-NH₂: H-Tyr-D-Arg-Phe-Phe-NH₂; H-Tyr-D-Cys-Phe-Phe-NH₂; H-Tyr-D-Thr-Phe-Phe-NH₂; H-DMT-D-Ser-Phe-Phe-NH₂; H-Tvr-D-Ala-Phe-Phe-OH trifluoroacetate: H-Tyr-D-Ala-Phe-Phg-NH₂ trifluoroacetic acid salt: H-Tyr-D-Arg-Phe-Hph-NH2 bis-trifluoroacetic acid; H-DMT-D-Ala-Phe-Phe-NH₂ trifluoroacetic acid; H-D-DMT-D-Ala-Phe-Phe-NH2 trifluoroacetic acid salt: H-Tyr-D-Ala-Phe-Hph-NH₂ trifluoroacetic acid salt; H-Tyr-D-Ala-Phe-Cys(Bzl)-NH2 trifluoroacetic acid salt: H-Tyr-D-Arg-Hph-Phe-NH2 bis-trifluoroacetic acid salt; 11-Tyr-D-Arg-Phg-Phc-N11₂ bis-trifluoro acetic acid salt: II-Tyr-D-Ala-Phe-Phe-Cl12011 hydrochloride salt: H-Tyr-D-Ala-Hph-Phe-NH₂ trifluoroacetic acid salt: II-Tyr-D-Met-Phe-Phe-NII₂ trifluoroacetic acid salt: II-Tyr-D-Arg-Phe-D-Phe-NH2 bis-trifluoroacetic acid salt: 11-Tyr-D-AIa-Phg-Phe-NH2 trifluoroacetic acid salt:

H-Tyr-(D)-Ala-(D)-Phg-Phe-NH₂ trifluoroacetic acid salt:

H-Eyr-D-Ala-Phe-Phe(pL)-NH: trifluoroacetic acid salt, and

.

Brown, *et al.* 09/994,078

H-Tyr-D-Ala-Phe-D-Phe(pF)-NH2 trifluoroacetic acid salt.